Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs

Stopped Development program ended due to inability to pair with other cytidine analogs and higher risk of hyperlipasemia when not used with 3TC/FTC.

Conditions

• HIV Infections
• Human Immunodeficiency Virus

Interventions

• DRUG: Dexelvucitabine

Sponsor

Incyte Corporation